Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The company patent portfolio for Ynios Pharma currently contains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner, BOATENG, AFUA BAMFOAA, who is situated in 1 distinct art unit. As the busiest examiner for the portfolio, BOATENG, AFUA BAMFOAA is responsible for the 1 busiest examiner pending office action. This concentration of 1 pending office action under 1 distinct examiner suggests a highly focused prosecution strategy at this stage.
For a practitioner, the involvement of 1 distinct art unit means that the technical review is confined to a specific niche within Biotechnology & Pharmaceuticals. The outcome of the company's current patent office engagement depends entirely on the 1 busiest examiner pending action. Because only 1 distinct examiner is involved, there is no diversification of examiner perspectives across the portfolio. This profile for Ynios Pharma reflects the current state of its intellectual property development and its focused approach to securing patent rights. Navigating the specific requirements of the assigned official is essential for advancing the case toward allowance.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOATENG, AFUA BAMFOAA | 1 | 46.7% | +64.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871069 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | BOATENG, AFUA BAMFOAA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18871069 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | BOATENG, AFUA BAMFOAA | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18871069 | MULTI-IONIC COMPLEX FOR THE PREVENTION OR TREATMENT OF INFLAMMATION | BOATENG, AFUA BAMFOAA | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYnios Pharma has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Afua Bamfoaa Boateng has the most, with 1 of Ynios Pharma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
